HER2 blockade in metastatic collecting duct carcinoma (cdc) of the kidney: A case report

25Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Background: Collecting duct carcinoma of the kidney (CDC) is a rare cancer associated with bad prognosis and, at present, with no specific effective therapies. Case Report: We report a clinical case with disseminated highgrade CDC presenting with widespread metastasis to both lungs, pelvic bones, axial skeleton, and the central nervous system (posterior fossa, both hemispheres and pituitary-hypothalamic). The primary tumor in the kidney was demonstrated (by fluorescence in situ hybridization and immunohistochemistry with Herceptest (3+ score)) to significantly overexpress HER2. Critically ill at presentation, the patient received oral capecitabine together with double HER2 blockade with both intravenous trastuzumab and oral lapatinib. His clinical response was a dramatic improvement and a progressive decline in the radiological size of all of his multiple cancer lesions. Conclusion: Double HER2 blockade is an effective therapy in disseminated CDC even in the presence of brain metastases. © 2012 S. Karger GmbH, Freiburg.

Cite

CITATION STYLE

APA

Bronchud, M. H., Castillo, S., Escriva De Romaní, S., Mourelo, S., Fernández, A., Baena, C., … Andreu, X. (2012). HER2 blockade in metastatic collecting duct carcinoma (cdc) of the kidney: A case report. Onkologie, 35(12), 776–779. https://doi.org/10.1159/000345041

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free